Sinopharm Group Co (HKSE:01099) Cash per Share : HK$14.95 (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Sinopharm Group Co's Cash per Share for the quarter that ended in Jun. 2024 was HK$14.95.

Sinopharm Group Co Cash per Share Historical Data

The historical data trend for Sinopharm Group Co's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Cash per Share Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

14.68

19.08

17.08

19.76

22.37

Sinopharm Group Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash per Share	Get a 7-Day Free Trial															12.08	19.76	12.05	22.37	14.95

Sinopharm Group Co Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Sinopharm Group Co's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	69793.03	/	3,121
	=	22.36

Sinopharm Group Co's Cash per Share for the quarter that ended in Jun. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	46649.126	/	3,121
	=	14.95

Sinopharm Group Co (HKSE:01099) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Sinopharm Group Co Cash per Share Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA X2S:Germany X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Executives

Lazard Asset Management Llc	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Zhong Xin Zheng Quan Yun Fan Dan Yi Zi Chan Guan Li Ji Hua	2501 Other
Zhong Xin Zheng Quan Zi Chan Guan Li You Xian Gong Si	2102 Investment manager
Citic Securities Company Limited	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Fmr Llc	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you

Sinopharm Group Co Headlines

No Headlines